New research found a link between GLP-1 use in people with diabetes and an elevated chance of wet AMD, which can cause blindness.

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. These drugs have transformed the treatment of type 2 diabetes by helping lower blood sugar levels and even reducing the risk of ...

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

Intravitreal anti-vascular epithelial growth factor (VEGF) therapies provide significant anatomical and visual-acuity benefits to patients with neovascular age-related macular degeneration (nAMD ...

The management of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) continues to evolve through the constant refinement of treatment protocols and ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% of ...

BARCELONA, Spain — Patients who receive a diagnosis of neovascular age-related macular degeneration (nAMD) from their primary care clinician may be less likely to adhere to treatment than those ...

Instead of receiving uncomfortable eye injections around once a month for a disease that can lead to blindness, patients may ...

STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who ...